Hearing Stability Following IGF ‐ 1R Inhibitor Treatment in Mice

OBJECTIVES: Teprotumumab is a novel monoclonal antibody treatment for thyroid eye disease that acts through IGF-1R inhibition. A subset of patients has been reported to experience varying levels of hearing change and other otologic symptoms after therapy. This study aimed to investigate auditory changes following monoclonal antibody IGF-1R inhibitor treatment in mice. METHODS: Adult CBA/CaJ mice were treated with varying doses of a chimeric IGF-1R monoclonal antibody (cIGF-1R mAb), saline, or IgG2a isotype controls (n = 10 per group) weekly for 20 weeks. Mice underwent auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing at regular intervals. Suprathreshold ABR Wave 1 amplitude growth functions were analyzed at the final timepoint, along with histological assessment of auditory hair cells and presynaptic ribbons. Bodyweight, exposure of cIGF-1R mAb, and the inhibitory effect of cIGF-1R mAb in lung tissues were also assessed. RESULTS: At 20 weeks, there was no significant increase in ABR or DPOAE threshold shift of the experimental cIGF-1R mAb groups compared with saline controls. No significant decrease in hair cell and presynaptic ribbon counts or suprathreshold ABR Wave 1 amplitude growth functions were observed amongst cIGF-1R mAb-treated subjects compared with saline controls. Inhibitory activity of cIGF-1R mAb was confirmed by the reduced bodyweight gain compared with controls and sustained IGF-1R pathway inhibition over the study period. CONCLUSION: IGF-1R inhibition in mice shows no consistent electrophysiologic or histological effect on auditory function. Further animal and clinical studies are warranted to evaluate a potential association between IGF-1R treatment and hearing loss. LEVEL OF EVIDENCE: N/A.

Authors

Institutions

Publication Details

Journal
The Laryngoscope
Published
2026-11-16
DOI
https://doi.org/10.1002/lary.71063
Primary Topic
Hearing, Cochlea, Tinnitus, Genetics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hearing Stability Following IGF ‐ 1R Inhibitor Treatment in Mice

Osama Tarabichi, Alexander D. Claussen, Kamelia Zerrouki, Mohamed Amine Lounis et al.
The Laryngoscope
Hearing, Cochlea, Tinnitus, Genetics
article

Hearing Stability Following IGF ‐ 1R Inhibitor Treatment in Mice

Osama Tarabichi, Alexander D. Claussen, Kamelia Zerrouki, Mohamed Amine Lounis, Giustino Carnevale, Marlan Rex Hansen, Md Fahad Hossain, Aditya Alluri, Mateo Salazar, David Redhage, Christopher Ward, Adam Vaske, Bryce Hunger, Caridad Naanep, Chang‐Rung Chen, Brajesh Kumar
article en

Abstract

OBJECTIVES: Teprotumumab is a novel monoclonal antibody treatment for thyroid eye disease that acts through IGF-1R inhibition. A subset of patients has been reported to experience varying levels of hearing change and other otologic symptoms after therapy. This study aimed to investigate auditory changes following monoclonal antibody IGF-1R inhibitor treatment in mice. METHODS: Adult CBA/CaJ mice were treated with varying doses of a chimeric IGF-1R monoclonal antibody (cIGF-1R mAb), saline, or IgG2a isotype controls (n = 10 per group) weekly for 20 weeks. Mice underwent auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing at regular intervals. Suprathreshold ABR Wave 1 amplitude growth functions were analyzed at the final timepoint, along with histological assessment of auditory hair cells and presynaptic ribbons. Bodyweight, exposure of cIGF-1R mAb, and the inhibitory effect of cIGF-1R mAb in lung tissues were also assessed. RESULTS: At 20 weeks, there was no significant increase in ABR or DPOAE threshold shift of the experimental cIGF-1R mAb groups compared with saline controls. No significant decrease in hair cell and presynaptic ribbon counts or suprathreshold ABR Wave 1 amplitude growth functions were observed amongst cIGF-1R mAb-treated subjects compared with saline controls. Inhibitory activity of cIGF-1R mAb was confirmed by the reduced bodyweight gain compared with controls and sustained IGF-1R pathway inhibition over the study period. CONCLUSION: IGF-1R inhibition in mice shows no consistent electrophysiologic or histological effect on auditory function. Further animal and clinical studies are warranted to evaluate a potential association between IGF-1R treatment and hearing loss. LEVEL OF EVIDENCE: N/A.

The Laryngoscope
University of Iowa (US), Amgen (United States) (US), Paraza Pharma (Canada) (CA)
Horizon Therapeutics
Good health and well-being
Hearing, Cochlea, Tinnitus, Genetics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon